Replies to post #2386 on Ocera Therapeutics fka OCRX

[puravida]

I am eagerly awaiting the corporate plan update regarding the bold portion!

'These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the date of the filing of this Form 10-K. Our ability to continue as a going concern and finance operations beyond our current resources will depend heavily on value investors see in the data from our previous clinical trials of OCR-002 and favorable results from any future clinical trials of OCR-002 we may conduct. We plan to raise additional capital through collaboration, licensing or similar arrangements, private and public equity offerings or debt financing, or a combination thereof. Additional financing may not be available when we need it or may not be available on terms that are favorable to us. Collaboration, licensing or similar arrangements may require us to relinquish valuable rights to our potential products or proprietary technologies. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing stockholders. '